Time-course effects of St John's wort on the pharmacokinetics of cyclosporine in dogs

被引:13
|
作者
Fukunaga, K. [1 ]
Orito, K. [1 ]
机构
[1] Azabu Univ, Sch Vet Med, Dept Physiol 2, Sagamihara, Kanagawa 2525201, Japan
关键词
A PHARMACOKINETICS; DRUG-METABOLISM; P-GLYCOPROTEIN; INDUCTION; DIGOXIN; EXTRACT;
D O I
10.1111/j.1365-2885.2011.01348.x
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Fukunaga, K., Orito, K. Time-course effects of St Johns wort on the pharmacokinetics of cyclosporine in dogs. J. vet. Pharmacol. Therap. 35, 446-451. To clarify the interaction between St Johns wort (SJW) and cyclosporine (CsA) in dogs, the pharmacokinetics of CsA before and during the repeated administration of SJW were analyzed. In the SJW group, SJW (300 mg) was given orally to four dogs every 24 h for 14 days. A single dose of CsA (5 mg/kg) was given orally 7 days before and 7 and 14 days after the initiation of the repeated administration of SJW. In the Control group, a single dose of CsA (5 mg/kg) was given orally to four other dogs in accordance with that in the SJW group. Blood samples from both groups were collected, and whole-blood concentrations of CsA were determined using high-performance liquid chromatography with UV detection. The maximum whole-blood concentration and AUC08 of the SJW group were significantly lower and the CLtot/F and Vd/F were significantly higher than those in the Control group 7 and 14 days after the initiation of repeated SJW. Thus, repeated administrations of SJW affect the pharmacokinetic profiles of CsA in dogs. Further studies are necessary to elucidate the mechanisms of interaction between SJW and CsA in dogs.
引用
收藏
页码:446 / 451
页数:6
相关论文
共 50 条
  • [21] Topical Application of St. John's Wort (Hypericum perforatum)
    Woelfle, Ute
    Seelinger, Guenter
    Schempp, Christoph M.
    PLANTA MEDICA, 2014, 80 (2-3) : 109 - 120
  • [23] Physiologically Based Pharmacokinetic Modelling of Hyperforin to Predict Drug Interactions with St John's Wort
    Adiwidjaja, Jeffry
    Boddy, Alan V.
    McLachlan, Andrew J.
    CLINICAL PHARMACOKINETICS, 2019, 58 (07) : 911 - 926
  • [24] Metabolism of hyperforin, the active constituent of St. John's wort, in human liver microsomes
    Hokkanen, Juho
    Tolonen, Ari
    Mattila, Sampo
    Turpeinen, Miia
    EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES, 2011, 42 (03) : 273 - 284
  • [25] Partial healing effects of St. John's wort oil on the rat excisional wound model
    Atsu, Ayse Nilhan
    Bilgic, Tayfun
    Kayhan, Cavit Kerem
    Saglam, Zumrut Mine Isik
    Caf, Nazli
    MARMARA MEDICAL JOURNAL, 2022, 35 (03): : 281 - 287
  • [26] Hypericum perforatum (St John's wort) beyond depression: A therapeutic perspective for pain conditions
    Galeotti, Nicoletta
    JOURNAL OF ETHNOPHARMACOLOGY, 2017, 200 : 136 - 146
  • [27] Integrated Metabolomics and Phytochemical Genomics Approaches for Studies on St, John's Wort
    Mafakheri, Saeideh
    Karami, Akbar
    NATURAL PRODUCTS JOURNAL, 2020, 10 (03): : 188 - 192
  • [28] St John's wort (Hypericum perforatum) products - an assessment of their authenticity and quality
    Booker, Anthony
    Agapouda, Anastasia
    Frommenwiler, Debora A.
    Scotti, Francesca
    Reich, Eike
    Heinrich, Michael
    PHYTOMEDICINE, 2018, 40 : 158 - 164
  • [29] St. John's Wort Formulations Induce Rat CYP3A23-3A1 Independent of Their Hyperforin ContentS
    Schaefer, Anima M.
    Rysz, Marta A.
    Schaedeli, Julia
    Huebscher, Michelle
    Khosravi, Haleh
    Fehr, Michelle
    Seibert, Isabell
    Potterat, Olivier
    Smiesko, Martin
    Meyer, Henriette E.
    MOLECULAR PHARMACOLOGY, 2024, 105 (01) : 14 - 22
  • [30] Gas chromatography for β-caryophyllene determination in St. John's wort infused oil
    Vickackaite, Vida
    Petrokaite, Sandra
    Poskus, Vilius
    CHEMIJA, 2022, 33 (04): : 181 - 189